case_images: PMC10140560_01
case_images: PMC10140560_02
case_images: Dynamics of PANSS negative subscale values in the course of therapy with Cariprazine.
case_images: fpsyt-14-1155518-g001.jpg
case_images: PMC10140560_02_fpsyt-14-1155518-g001.jpg
case_images: fig1
case_images: After 18 months of Cariprazine - at a 4.5 mg daily dose, the positive subscale of PANSS showed relatively no significant change, but the negative subscale mean score decreased by 29.8% (Figure 1).
case_images: Dynamics of the overall PANSS mean score in the course of therapy with Cariprazine.
case_images: fpsyt-14-1155518-g002.jpg
case_images: PMC10140560_02_fpsyt-14-1155518-g002.jpg
case_images: fig2
case_images: The overall PANSS mean score decreased by 23.8% (Figure 2), CGI-S mean score improved by 25%, and the mean GAF score increased by 29.5% (Figure 3).
case_images: Dynamics of the mean GAF scores in the course of therapy with Cariprazine.
case_images: fpsyt-14-1155518-g003.jpg
case_images: PMC10140560_02_fpsyt-14-1155518-g003.jpg
case_images: fig3
case_images: The overall PANSS mean score decreased by 23.8% (Figure 2), CGI-S mean score improved by 25%, and the mean GAF score increased by 29.5% (Figure 3).